Compare CRAI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | DBVT |
|---|---|---|
| Founded | 1965 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1998 | 2014 |
| Metric | CRAI | DBVT |
|---|---|---|
| Price | $161.79 | $19.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $245.00 | $32.04 |
| AVG Volume (30 Days) | 148.8K | ★ 186.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 20.77 | 10.26 |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | $5,636,000.00 |
| Revenue This Year | $7.82 | $35.04 |
| Revenue Next Year | $5.14 | $2,360.78 |
| P/E Ratio | $19.97 | ★ N/A |
| Revenue Growth | 9.33 | ★ 35.77 |
| 52 Week Low | $142.53 | $7.53 |
| 52 Week High | $227.29 | $26.19 |
| Indicator | CRAI | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 42.35 |
| Support Level | $152.81 | $18.88 |
| Resistance Level | $167.66 | $23.52 |
| Average True Range (ATR) | 6.04 | 0.83 |
| MACD | 0.98 | -0.08 |
| Stochastic Oscillator | 82.70 | 10.78 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.